{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:32:46Z","timestamp":1794918766284,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging has revolutionized prostate cancer detection and management. This review aims to evaluate the latest advancements in PSMA PET imaging, assess its clinical applications in various disease stages, and compare it to conventional imaging techniques. We sought to determine how PSMA PET impacts clinical decision-making, treatment strategies, and patient outcomes, with a focus on its expanding role in precision oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent studies have demonstrated that PSMA PET exhibits superior sensitivity and specificity in detecting prostate cancer metastases, particularly in cases of biochemical recurrence and early-stage disease. The advent of radiolabeled PSMA ligands, such as 68Ga-PSMA-11 and 18\u00a0F-DCFPyL, has led to improved diagnostic accuracy. Furthermore, PSMA-targeted radioligand therapies (e.g., 177Lu-PSMA-617) show promising results in metastatic castration-resistant prostate cancer (mCRPC), offering a novel therapeutic avenue. Studies have also highlighted the role of PSMA PET in refining treatment plans, including guiding surgery and radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>PSMA PET imaging represents a paradigm shift in prostate cancer diagnostics, staging, and treatment monitoring. It has led to earlier and more accurate detection of metastases, significantly altering management strategies. The growing body of evidence supports its integration into standard-of-care protocols, with ongoing research focusing on optimizing its therapeutic applications. Future studies should explore cost-effectiveness, accessibility, and potential synergies with emerging systemic therapies to further enhance patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11934-025-01268-2","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T03:48:11Z","timestamp":1748663291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Role of PSMA PET Imaging in Prostate Cancer: Current Applications and Future Directions"],"prefix":"10.1007","volume":"26","author":[{"given":"Raeesa","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrijal","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Golombos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"issue":"13","key":"1268_CR1","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3390\/diagnostics14131315","volume":"14","author":"A Alshamrani","year":"2024","unstructured":"Alshamrani A. Diagnostic accuracy of molecular imaging techniques for detecting prostate cancer: a systematic review. Diagnostics. 2024;14(13):1315. https:\/\/doi.org\/10.3390\/diagnostics14131315.","journal-title":"Diagnostics"},{"issue":"3","key":"1268_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2016","unstructured":"Cardinale J, Sch\u00e4fer M, Bene\u0161ov\u00e1 M, Bauder-W\u00fcst U, Leotta K, Eder M, Kopka K. Preclinical evaluation of 18f-psma-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med. 2016;58(3):425\u201331. https:\/\/doi.org\/10.2967\/jnumed.116.181768.","journal-title":"J Nucl Med"},{"key":"1268_CR3","doi-asserted-by":"publisher","unstructured":"McGeorge, S., Kwok, M., Jiang, A., Emmett, L., Pattison, D., Thomas, P.,\u2026 Roberts,M. (2021). Dual-tracer positron-emission tomography using prostate-specific membrane antigen and fluorodeoxyglucose for staging of prostate cancer: a systematic review.Advances in Urology, 2021, 1\u20139. https:\/\/doi.org\/10.1155\/2021\/1544208.","DOI":"10.1155\/2021\/1544208"},{"key":"1268_CR4","doi-asserted-by":"publisher","unstructured":"Liu, C., Liu, T., Zhang, Z., Zhang, N., Du, P., Yang, Y.,\u2026 Liu, Y. (2020). 68ga-psma pet\/ct combined with pet\/ultrasound-guided prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsy results. Journal of Nuclear Medicine, 61(9), 1314\u20131319. https:\/\/doi.org\/10.2967\/jnumed.119.235333.","DOI":"10.2967\/jnumed.119.235333"},{"key":"1268_CR5","doi-asserted-by":"publisher","unstructured":"Kesch, C., Vinsensia, M., Radtke, J., Schlemmer, H., Heller, M., Ellert, E.,\u2026 Giesel, F. (2017). Intraindividual comparison of 18f-psma-1007 pet\/ct, multiparametric mri, and radical prostatectomy specimens in patients with primary prostate cancer:a retrospective, proof-of-concept study. Journal of Nuclear Medicine, 58(11), 1805\u20131810. https:\/\/doi.org\/10.2967\/jnumed.116.189233.","DOI":"10.2967\/jnumed.116.189233"},{"key":"1268_CR6","doi-asserted-by":"publisher","unstructured":"Petersen L, Zacho H. Psma pet for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging. 2020;20(1). https:\/\/doi.org\/10.1186\/s40644-020-0290-9.","DOI":"10.1186\/s40644-020-0290-9"},{"key":"1268_CR7","doi-asserted-by":"publisher","unstructured":"Zou, S., Song, S., Zhou, J., B, Y., Kuang, D., Wang, Z.,\u2026 Zhu, X. (2022). Time point-independent tumor positivity of 68ga-psma-pet\/ct pre- and post-biopsy in high-risk prostate cancer.Annals of Nuclear Medicine, 36(6), 523\u2013532.https:\/\/doi.org\/10.1007\/s12149-022-01732-w.","DOI":"10.1007\/s12149-022-01732-w"},{"key":"1268_CR8","doi-asserted-by":"publisher","unstructured":"Aydos, U., \u00c7etin, S., Akdemir, \u00dc., Budak, F., Ate\u015f, S., Koparal, M.,\u2026 Atay, L. (2021).The role of histopathological and biochemical parameters for predicting metastatic disease on 68ga-psma\u201011 pet in prostate cancer. The Prostate, 81(16), 1337\u20131348. https:\/\/doi.org\/10.1002\/pros.24231.","DOI":"10.1002\/pros.24231"},{"issue":"6","key":"1268_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/1754-9485.13084","volume":"64","author":"D Brauchli","year":"2020","unstructured":"Brauchli D, Singh D, Chabert C, Somasundaram A, Collie L. Tumour\u2013capsule interface measured on 18f-dcfpyl Psma positron emission tomography\/ct imaging comparable to multi\u2010parametric mri in predicting extra\u2010prostatic extension of prostate cancer at initial staging. J Med Imaging Radiat Oncol. 2020;64(6):829\u201338. https:\/\/doi.org\/10.1111\/1754-9485.13084.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1268_CR10","doi-asserted-by":"publisher","unstructured":"Gao, X., Tang, Y., Chen, M., Li, J., Yin, H., Gan, Y.,\u2026 Hu, S. (2022). A prospective comparative study of 68ga-rm26 and 68ga-psma-617 pet\/ct imaging in suspicious prostate cancer. https:\/\/doi.org\/10.21203\/rs.3.rs-2175723\/v1.","DOI":"10.21203\/rs.3.rs-2175723\/v1"},{"key":"1268_CR11","doi-asserted-by":"publisher","unstructured":"Fassbender, T., Schiller, F., Zamboglou, C., Drendel, V., Kiefer, S., Jilg, C.,\u2026Mix, M. (2020). Voxel-based comparison of [68ga]ga-rm2-pet\/ct and [68ga]ga-psma-11-pet\/ct with histopathology for diagnosis of primary prostate cancer. Ejnmmi Research, 10(1). https:\/\/doi.org\/10.1186\/s13550-020-00652-y.","DOI":"10.1186\/s13550-020-00652-y"},{"issue":"13","key":"1268_CR12","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.3390\/cancers15133402","volume":"15","author":"A Hoffman","year":"2023","unstructured":"Hoffman A, Amiel G. The impact of Psma Pet\/ct on modern prostate cancer management and decision making\u2014the urological perspective. Cancers. 2023;15(13):3402. https:\/\/doi.org\/10.3390\/cancers15133402.","journal-title":"Cancers"},{"key":"1268_CR13","doi-asserted-by":"publisher","unstructured":"Rahbar, K., Weckesser, M., Huss, S., Semjonow, A., Breyholz, H., Schrader, A.,\u2026 B\u00f6gemann,M. (2016). Correlation of intraprostatic tumor extent with 68ga-psma distribution in patients with prostate cancer. Journal of Nuclear Medicine, 57(4), 563\u2013567.https:\/\/doi.org\/10.2967\/jnumed.115.169243.","DOI":"10.2967\/jnumed.115.169243"},{"key":"1268_CR14","doi-asserted-by":"publisher","unstructured":"Fendler, W., Calais, J., Eiber, M., Flavell, R., Mishoe, A., Feng, F.,\u2026 Hope, T.(2019). Assessment of 68ga-psma-11 pet accuracy in localizing recurrent prostate cancer.Jama Oncology, 5(6), 856. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","DOI":"10.1001\/jamaoncol.2019.0096"},{"key":"1268_CR15","doi-asserted-by":"publisher","unstructured":"Chen et al. 18F-PSMA-1007 PET\/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report translational andrology and urology (2021) https:\/\/doi.org\/10.21037\/tau-20-1099","DOI":"10.21037\/tau-20-1099"},{"key":"1268_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1148\/radiol.2018181278","volume":"290","author":"S Mehralivand","year":"2019","unstructured":"Mehralivand S, Shih JH, Harmon S, et al. A grading system for the assessment of risk of extraprostatic extension of prostate Cancer at multiparametric MRI. Radiology. 2019;290:709\u201319. https:\/\/doi.org\/10.1148\/radiol.2018181278.","journal-title":"Radiology"},{"issue":"9","key":"1268_CR17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00345-018-2295-6","volume":"36","author":"BHE Jansen","year":"2018","unstructured":"Jansen BHE, Oudshoorn FHK, Tijans AM, Yska MJ, Lont AP, Collette ERP, Nieuwenhuijzen JA, Vis AN. Local staging with multiparametric MRI in daily clinical practice: diagnostic accuracy and evaluation of a radiologic learning curve. World J Urol. 2018;36(9):1409\u201315. https:\/\/doi.org\/10.1007\/s00345-018-2295-6. Epub 2018 Apr 21. PMID: 29680949; PMCID: PMC6105169.","journal-title":"World J Urol"},{"issue":"1","key":"1268_CR18","doi-asserted-by":"publisher","first-page":"48e","DOI":"10.1016\/j.urolonc.2022.10.003","volume":"41","author":"CD Bahler","year":"2023","unstructured":"Bahler CD, Green MA, Tann MA, Swensson JK, Collins K, Alexoff D, Kung H, Brocken E, Mathias CJ, Cheng L, Hutchins GD, Koch MO. Assessing extra-prostatic extension for surgical guidance in prostate cancer: comparing two PSMA-PET tracers with the standard-of-care. Urol Oncol. 2023;41(1):48e. 1-48.e9..Epub 2022 Nov 1. PMID: 36333187.","journal-title":"Urol Oncol"},{"issue":"4","key":"1268_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s13139-017-0476-7","volume":"51","author":"CJ von Klot","year":"2017","unstructured":"von Klot CJ, Merseburger AS, B\u00f6ker A, Schmuck S, Ross TL, Bengel FM, Kuczyk MA, Henkenberens C, Christiansen H, Wester HJ, Solass W, Lafos M, Derlin T. 68Ga-PSMA PET\/CT imaging predicting intraprostatic tumor extent, extracapsular extension and seminal vesicle invasion prior to radical prostatectomy in patients with prostate Cancer. Nucl Med Mol Imaging. 2017;51(4):314\u201322. https:\/\/doi.org\/10.1007\/s13139-017-0476-7. Epub 2017 Mar 7. PMID: 29242725; PMCID: PMC5721087.","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"1268_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/pros.24799","volume":"85","author":"M Dinckal","year":"2025","unstructured":"Dinckal M, Ergun KE, Kalemci MS, Guler E, Tokac R, Ordu S, Ogut N, Ozgul S, Sanli O, Sen S, Turna B. Head-to-head comparison of GA-68 PSMA PET\/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer. Prostate. 2025;85(1):48\u201357. Epub 2024 Sep 30. PMID: 39345022; PMCID: PMC11609967.","journal-title":"Prostate"},{"issue":"2","key":"1268_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/JU.0000000000004032","volume":"212","author":"CD \u2022Bahler","year":"2024","unstructured":"\u2022Bahler CD, Tachibana I, Tann M, Collins K, Swensson JK, Green MA, Mathias CJ, Tong Y, Yong C, Boris RS, Brocken E, Hutchins GD, Sims JB, Hill DV, Smith N, Ferari C, Love H, Koch MO. Comparing magnetic resonance imaging and prostate-Specific membrane Antigen-Positron emission tomography for prediction of extraprostatic extension of prostate Cancer and surgical guidance: A prospective nonrandomized clinical trial. J Urol. 2024;212(2):290\u20138. Epub 2024 May 24.","journal-title":"J Urol"},{"issue":"1","key":"1268_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","volume":"5","author":"A \u2022Stabile","year":"2022","unstructured":"\u2022Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, Scuderi S, Cucchiara V, Gandaglia G, Raggi D, Necchi A, Karakiewicz P, Montorsi F, Briganti A. Can negative prostate-specific membrane antigen positron emission tomography\/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate Cancer patients?? A systematic review and Meta-analysis with backup histology as reference standard. Eur Urol Oncol. 2022;5(1):1\u201317. Epub 2021 Sep 17. PMID: 34538770.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"1268_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.urolonc.2023.12.016","volume":"42","author":"NA \u2022J Huebner","year":"2024","unstructured":"\u2022J Huebner NA, Wasinger G, Rajwa P, Resch I, Korn S, Rasul S, Baltzer P, Pr\u00fcger L, Rauschmeier A, Seitz C, Comperat E, Shariat SF, Grubm\u00fcller B. Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET. Urol Oncol. 2024;42(4):115..e9-115.e16. Epub 2024 Jan 20. PMID: 38246806.","journal-title":"Urol Oncol"},{"key":"1268_CR24","doi-asserted-by":"publisher","unstructured":"Pasoglou, V., Larbi, A., Collette, L., Annet, L., Jamar, F., Machiels, J.,\u2026 Lecouvet,F. (2013). One-step tnm staging of high\u2010risk prostate cancer using magnetic resonance imaging (mri): toward an upfront simplified all\u2010in\u2010one imaging approach? The Prostate,74(5), 469\u2013477. https:\/\/doi.org\/10.1002\/pros.22764.","DOI":"10.1002\/pros.22764"},{"issue":"10","key":"1268_CR25","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.3390\/jcm13102774","volume":"13","author":"E Karaca","year":"2024","unstructured":"Karaca E. Predictors of metastasis in 68ga-prostate specific membrane antigen pet-ct in the primary staging of prostate cancer. J Clin Med. 2024;13(10):2774. https:\/\/doi.org\/10.3390\/jcm13102774.","journal-title":"J Clin Med"},{"key":"1268_CR26","doi-asserted-by":"publisher","unstructured":"Koerber, S., Utzinger, M., Kratochwil, C., Kesch, C., Haefner, M., Katayama, S.,\u2026Giesel, F. (2017). 68ga-psma-11 pet\/ct in newly diagnosed carcinoma of the prostate:correlation of intraprostatic psma uptake with several clinical parameters. Journal of Nuclear Medicine, 58(12), 1943\u20131948. https:\/\/doi.org\/10.2967\/jnumed.117.190314.","DOI":"10.2967\/jnumed.117.190314"},{"key":"1268_CR27","doi-asserted-by":"publisher","unstructured":"Sonni, I., Felker, E., Sisk, A., Bahri, S., Allen-Auerbach, M., Armstrong, W.,\u2026 Calais,J. (2021). Head-to-head comparison of 68ga-psma-11 pet\/ct and mpmri with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial. Journal of Nuclear Medicine, 63(6), 847\u2013854.https:\/\/doi.org\/10.2967\/jnumed.121.262398.","DOI":"10.2967\/jnumed.121.262398"},{"issue":"4","key":"1268_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1590\/0100-3984.2022.0122-en","volume":"56","author":"C Stasiak","year":"2023","unstructured":"Stasiak C. Preoperative evaluation of prostate cancer by 68ga-pmsa positron emission tomography\/computed tomography: comparison with magnetic resonance imaging and with histopathological findings. Radiologia Brasileira. 2023;56(4):171\u20138. https:\/\/doi.org\/10.1590\/0100-3984.2022.0122-en.","journal-title":"Radiologia Brasileira"},{"key":"1268_CR29","doi-asserted-by":"publisher","unstructured":"Liu, Y., Niu, S., Luan, X., Zhang, X., Liu, J., Zhang, J.,\u2026 Zhang, X. (2023). Can 18f-psma-7q pet\/ct replace prostate biopsy for the diagnosis of prostate cancer?\u2014a single-center retrospective study. Translational Andrology and Urology, 12(1), 83\u201389. https:\/\/doi.org\/10.21037\/tau-22-813.","DOI":"10.21037\/tau-22-813"},{"key":"1268_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13739","author":"Albisinni","year":"2017","unstructured":"Albisinni, et al. Clinical impact of 68Ga-prostate\u2010specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) in patients with prostate cancer with rising prostate\u2010specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int. 2017. https:\/\/doi.org\/10.1111\/bju.13739.","journal-title":"BJU Int"},{"key":"1268_CR31","doi-asserted-by":"publisher","unstructured":"Bouchelouche et al. PSMA PET and radionuclide therapy in prostate Cancer seminars in nuclear medicine (2016) https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.07.006","DOI":"10.1053\/j.semnuclmed.2016.07.006"},{"key":"1268_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3882-2","author":"Virgolini","year":"2017","unstructured":"Virgolini, et al. Current status of theranostics in prostate cancer. Eur J Nucl Med. 2017. https:\/\/doi.org\/10.1007\/s00259-017-3882-2.","journal-title":"Eur J Nucl Med"},{"key":"1268_CR33","doi-asserted-by":"publisher","unstructured":"Cimadamore, A., Cheng, M., Santoni, M., L\u00f3pez-Beltr\u00e1n, A., Battelli, N., Massari,F.,\u2026 Montironi, R. (2018). New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen. Frontiers in Oncology, 8.https:\/\/doi.org\/10.3389\/fonc.2018.00653.","DOI":"10.3389\/fonc.2018.00653"},{"key":"1268_CR34","doi-asserted-by":"publisher","unstructured":"Giesel, F., Knorr, K., Spohn, F., Will, L., Maurer, T., Flechsig, P.,\u2026 Eiber, M.(2018). Detection efficacy of 18f-psma-1007 pet\/ct in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. Journal of Nuclear Medicine,60(3), 362\u2013368. https:\/\/doi.org\/10.2967\/jnumed.118.212233.","DOI":"10.2967\/jnumed.118.212233"},{"key":"1268_CR35","doi-asserted-by":"publisher","unstructured":"Uijen, M., Derks, Y., Merkx, R., Schilham, M., Roosen, J., Priv\u00e9, B.,\u2026 Nagarajah,J. (2021). Psma radioligand therapy for solid tumors other than prostate cancer: background,opportunities, challenges, and first clinical reports. European Journal of Nuclear Medicine, 48(13), 4350\u20134368. https:\/\/doi.org\/10.1007\/s00259-021-05433-w.","DOI":"10.1007\/s00259-021-05433-w"},{"issue":"2","key":"1268_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/mnm.0000000000001792","volume":"45","author":"K Kaur","year":"2023","unstructured":"Kaur K. Estimation of absorbed dose to salivary glands in Mcrpc patients undergoing 177 lu- psma-617 radioligand therapy using quantitative spect-ct at single time point: a single-center feasibility study. Nucl Med Commun. 2023;45(2):115\u201320. https:\/\/doi.org\/10.1097\/mnm.0000000000001792.","journal-title":"Nucl Med Commun"},{"issue":"5","key":"1268_CR37","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3390\/pharmaceutics13050699","volume":"13","author":"E Sar","year":"2021","unstructured":"Sar E, Keizer B, Lam M, Braat A. Competition (\u2018steal\u2019 phenomenon) between [68ga]ga-psma-11 uptake in prostate tumor tissue versus healthy tissue. Pharmaceutics. 2021;13(5):699. https:\/\/doi.org\/10.3390\/pharmaceutics13050699.","journal-title":"Pharmaceutics"},{"key":"1268_CR38","doi-asserted-by":"publisher","unstructured":"Gaertner, F., Halabi, K., Ahmadzadehfar, H., K\u00fcrpig, S., Eppard, E., Kotsikopoulos,C.,\u2026 Essler, M. (2017). Uptake of psma-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget, 8(33), 55094\u201355103.https:\/\/doi.org\/10.18632\/oncotarget.19049.","DOI":"10.18632\/oncotarget.19049"},{"key":"1268_CR39","doi-asserted-by":"publisher","unstructured":"Singh, B., Sharma, S., Bansal, P., Hooda, M., Singh, H., Parihar, A.,\u2026 Singh, S.(2020). Comparison of the diagnostic utility of 99mtc-psma scintigraphy versus 68ga-psma-11 pet\/ct in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality. Nuclear Medicine Communications,42(5), 482\u2013489. https:\/\/doi.org\/10.1097\/mnm.0000000000001361.","DOI":"10.1097\/mnm.0000000000001361"},{"key":"1268_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-023-01881-y","author":"E Mamlins","year":"2023","unstructured":"Mamlins E. Mol Imaging Biology. 2023;26(1):81\u20139. https:\/\/doi.org\/10.1007\/s11307-023-01881-y. The theranostic optimization of psma-gck01 does not compromise the imaging characteristics of [99mtc]tc-psma-gck01 compared to dedicated diagnostic [99mtc]tc-edda\/hynic-ipsma in prostate cancer."},{"key":"1268_CR41","doi-asserted-by":"publisher","unstructured":"Banerjee, S., Kumar, V., Lisok, A., Plyku, D., Nov\u00e1kov\u00e1, Z., Brummet, M.,\u2026 Pomper,M. (2018). Evaluation of 111in-dota-5d3, a surrogate spect imaging agent for radioimmunotherapy of prostate-specific membrane antigen. Journal of Nuclear Medicine, 60(3), 400\u2013406.https:\/\/doi.org\/10.2967\/jnumed.118.214403.","DOI":"10.2967\/jnumed.118.214403"},{"key":"1268_CR42","doi-asserted-by":"publisher","unstructured":"Wong, H., Leung, J., Bartholomeusz, D., Sutherland, P., Le, H., Nottage, M.,\u2026 Chang,J. (2018). Comparative study between 68ga-prostate\u2010specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer.Journal of Medical Imaging and Radiation Oncology, 62(6), 816\u2013822. https:\/\/doi.org\/10.1111\/1754-9485.12791.","DOI":"10.1111\/1754-9485.12791"},{"issue":"14","key":"1268_CR43","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.3390\/cancers14143302","volume":"14","author":"S Galgano","year":"2022","unstructured":"Galgano S, McDonald A, West J, Rais-Bahrami S. Defining oligometastatic disease in the new era of psma-pet imaging for primary staging of prostate cancer. Cancers. 2022;14(14):3302. https:\/\/doi.org\/10.3390\/cancers14143302.","journal-title":"Cancers"},{"key":"1268_CR44","doi-asserted-by":"publisher","unstructured":"Veveris-Lowe, T., Lawrence, M., Collard, R., Bui, L., Herington, A., Nicol, D.,\u2026Clements, J. (2005). Kallikrein 4 (hk4) and prostate-specific antigen (psa) are associated with the loss of e-cadherin and an epithelial-mesenchymal transition (emt)-like effect in prostate cancer cells. Endocrine Related Cancer, 12(3), 631\u2013643. https:\/\/doi.org\/10.1677\/erc.1.00958.","DOI":"10.1677\/erc.1.00958"},{"issue":"2","key":"1268_CR45","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/bju.12671","volume":"115","author":"D Danneman","year":"2015","unstructured":"Danneman D, Drevin L, Robinson D, Stattin P, Egevad L. Gleason inflation 1998\u20132011: a registry study of 97 168 men. Br J Urol. 2015;115(2):248\u201355. https:\/\/doi.org\/10.1111\/bju.12671.","journal-title":"Br J Urol"},{"key":"1268_CR46","doi-asserted-by":"publisher","unstructured":"Moore, A., Dimitropoulou, P., Lane, A., Powell, P., Greenberg, D., Brown, C.,\u2026 Neal,D. (2009). Population-based prostate\u2010specific antigen testing in the uk leads to a stage migration of prostate cancer. British Journal of Urology, 104(11), 1592\u20131598. https:\/\/doi.org\/10.1111\/j.1464-410x.2009.08652.","DOI":"10.1111\/j.1464-410x.2009.08652"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01268-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-025-01268-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01268-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:02:51Z","timestamp":1767985371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-025-01268-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1268"],"URL":"https:\/\/doi.org\/10.1007\/s11934-025-01268-2","relation":{"references":[{"id-type":"doi","id":"10.1007\/s11307-023-01881-y","asserted-by":"subject"}]},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"15 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"and Human and Animal Rights Statements\n                      This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"46"}}